Adherium plans Aussie IPO for smart inhaler; FDA clears latest Gamma Knife;

@FierceMedDev: Mevion moves on from IPO to up to $200M JV backed by China, U.S. investors. Article | Follow @FierceMedDev

@StacyALawrence: Boston Sci ups cardiac monitoring, partners with wearable patch startup Preventice. Story | Follow @StacyALawrence

@VarunSaxena2: IYCMI: Citing cybersecurity concerns, FDA says not to use Hospira infusion pump. Article | Follow @VarunSaxena2

@EmilyWFierce: FDA doubles down on duodenoscope safety with list of cleaning recs. Report | Follow @EmilyWFierce

> Adherium plans an IPO to raise up to AU$35 million ($25.7 million) on the Australian Securities Exchange (ASX) to support its medication adherence technologies including the Smartinhaler to improve inhaler compliance for chronic respiratory disease and asthma patients. More

> FDA has cleared the latest Leksell Gamma Knife System, Icon, from Elekta to be used in combination with stereotactic imaging during brain surgery. More

> Molecular diagnostics player Provista Diagnostics has raised $6 million in a Series A-2 round from existing investors. More

Biotech News

@FierceBiotech: Baxalta to Shire: The answer is still 'no.' Article | Follow @FierceBiotech

@JohnCFierce: Mystery solved: Star biotech team rallies behind a $36M diabetes spinout from Salk. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Cannabis patch startup plots a $42M IPO to fund drugs for epilepsy, pain. Story

> Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute. Article

> Intec Pharma stumbles to $30M IPO as Parkinson's program fails to excite investors. More

Pharma News

@FiercePharma: Lilly faces first trial over claims of Cymbalta withdrawal symptoms. Report | Follow @FiercePharma

@EricPFierce: FDA may add Baxter saline Mexico plant to U.S. supply. Now if Baxter can just quit having to recall saline. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: DME data helps Eylea soar in Q2--and poach market share from its Roche rivals. Article | Follow @CarlyHFierce

> Novo Nordisk launches diabetes 'dream team' contest with NBA star as a prize. Item

> With more consolidation on tap in generics, who's next to buy and be bought? Article

> Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offer. More

Biotech Research News

> Study IDs a new pathway for drug research into calorie-burning brown fat. Report

> Scripps team finds a drug that fights addiction by eliminating memories. More

> BU researchers identify a new, more precise target for breast cancer. Story

> Virus-like nanoparticle vaccine used to guard against RSV. Item

> Uppsala University points to anti-inflammatory IL-35 as beneficial in pre-clinical Type 1 diabetes. Article

Diagnostics News

> UC Berkeley researchers create faster form of DNA amplification using LED lighting. Article

> NIH study finds blood biomarker for traumatic brain injury using sensitive analyzer. Story

> Foundation Medicine trips in Q2 with sluggish test reimbursement. More

> OraSure gets FDA nod for emergency use of rapid Ebola test. Report

> Illumina sends off first three companies from genomics startup incubator. Article

Pharma Marketing News

> Allergan taps purple-haired millennial mascot for hashtag-heavy women's health push. Story

> CVS creates one-on-one diabetes rivalries with new formulary exclusions. Report

> Pharma leaves ad agencies behind for in-house digital marketing teams. More

> Pfizer nabs rights to Copaxone copycats, setting up head-to-head generics fight with Novartis. Story

> Slam dunk: Novo Nordisk re-signs NBA Hall of Famer for Victoza marketing. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.